Publication | Closed Access

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Breast OncologyOncologyPharmacologySubcutaneous InjectionBreast CancerPharmacotherapyCancer TreatmentMedicineFixed-dose Combination